{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T11:47:06Z","timestamp":1764848826033,"version":"3.46.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"9-10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.rmr.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:42:21Z","timestamp":1764103341000},"page":"481-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-TNF-a\u00a0: indications et toxicit\u00e9 en pneumologie"],"prefix":"10.1016","volume":"42","author":[{"given":"I.","family":"Elhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bourgarit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2025.10.001_bib0275","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rmr.2025.10.001_bib0280","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-\u03b1: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.rmr.2025.10.001_bib0285","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/jdv.13246","article-title":"TNF -\u03b1: a treatment target or cause of sarcoidosis\u00a0?","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0290","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"4","author":"Broos","year":"2013","journal-title":"Front Immunol [Internet]"},{"issue":"3","key":"10.1016\/j.rmr.2025.10.001_bib0295","article-title":"The NLRP3\u00a0inflammasome pathway is activated in sarcoidosis and involved in granuloma formation","volume":"55","author":"Huppertz","year":"2020","journal-title":"Eur Respir J [Internet]"},{"key":"10.1016\/j.rmr.2025.10.001_bib0300","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pharmthera.2017.06.008","article-title":"Anti-TNF\u03b1 therapy in inflammatory lung diseases","volume":"180","author":"Malaviya","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.rmr.2025.10.001_bib0305","unstructured":"J.-C Richard. EM-Consulte. [cit\u00e9 5\u00a0d\u00e9c 2024]. Syndrome de d\u00e9tresse respiratoire aigu\u00eb. Disponible sur\u00a0: https:\/\/www.em-consulte.com\/article\/1676211\/figures\/syndrome-de-detresse-respiratoire-aigue."},{"key":"10.1016\/j.rmr.2025.10.001_bib0310","doi-asserted-by":"crossref","first-page":"L426","DOI":"10.1152\/ajplung.00302.2004","article-title":"Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury","volume":"288","author":"Parsons","year":"2005","journal-title":"Am J Physiol-Lung Cell Mol Physiol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0315","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.gendis.2020.02.004","article-title":"Therapeutic potential of TNF\u03b1 inhibitors in chronic inflammatory disorders: Past and future","volume":"8","author":"Zhang","year":"2021","journal-title":"Genes Dis"},{"key":"10.1016\/j.rmr.2025.10.001_bib0320","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0325","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejim.2022.12.003","article-title":"Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis","volume":"109","author":"Rezaee","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rmr.2025.10.001_bib0330","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12931-024-02758-6","article-title":"Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55\u00a0patients","volume":"25","author":"Rivi\u00e8re","year":"2024","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2025.10.001_bib0335","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","article-title":"Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety","author":"Adler","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rmr.2025.10.001_bib0340","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2025.10.001_bib0345","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1164\/rccm.200709-1446OC","article-title":"Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial","volume":"178","author":"Raghu","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2025.10.001_bib0350","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023\u00a0American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0355","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semarthrit.2009.09.001","article-title":"Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk","volume":"40","author":"Khasnis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rmr.2025.10.001_bib0360","doi-asserted-by":"crossref","first-page":"ofae327","DOI":"10.1093\/ofid\/ofae327","article-title":"Tuberculosis and immune reconstitution inflammatory syndrome in patients with inflammatory bowel disease and anti-TNF\u03b1 treatment: insights from a french multicenter study and systematic literature review with emphasis on paradoxical anti-TNF\u03b1 resumption","volume":"11","author":"Amoura","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.rmr.2025.10.001_bib0365","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.10.001_bib0370","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2015.04.022","article-title":"Paradoxical anti-TNF-associated TB worsening: frequency and factors associated with IRIS","volume":"83","author":"Rivoisy","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.rmr.2025.10.001_bib0375","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1086\/598504","article-title":"Adalimumab treatment of life-threatening tuberculosis","volume":"48","author":"Wallis","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2025.10.001_bib0380","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cmi.2024.04.011","article-title":"(Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review","volume":"30","author":"Brehm","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2025.10.001_bib0385","doi-asserted-by":"crossref","first-page":"8187","DOI":"10.3390\/ijms24098187","article-title":"Focus on anti-tumour necrosis factor (TNF)-\u03b1-related autoimmune diseases","volume":"24","author":"Lopetuso","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rmr.2025.10.001_bib0390","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/children11111366","article-title":"Infusion Reactions to Infliximab in Pediatric Patients with Inflammatory Bowel Disease","volume":"11","author":"Dharmaraj","year":"2024","journal-title":"Children"},{"key":"10.1016\/j.rmr.2025.10.001_bib0395","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related infusion reactions: systematic review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rmr.2025.10.001_bib0400","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","article-title":"Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice","volume":"55","author":"Schaeverbeke","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.rmr.2025.10.001_bib0405","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaad.2012.08.048","article-title":"Antinuclear antibodies do not predict anti-infliximab antibody induction in sarcoidosis","volume":"69","author":"Vorselaars","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0410","doi-asserted-by":"crossref","first-page":"e2323098","DOI":"10.1001\/jamanetworkopen.2023.23098","article-title":"Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies","volume":"6","author":"Bitoun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rmr.2025.10.001_bib0415","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.rmr.2025.10.001_bib0420","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-\u03b1 inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2025.10.001_bib0425","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.reuma.2020.04.015","article-title":"Systematic review of the impact of drugs on diffuse interstitial lung disease associated with rheumatoid arthritis","volume":"17","author":"Carrasco Cubero","year":"2021","journal-title":"Reumatol Cl\u00ednica Engl Ed"},{"key":"10.1016\/j.rmr.2025.10.001_bib0430","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/DDDT.S204730","article-title":"Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.rmr.2025.10.001_bib0435","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rmr.2025.10.001_bib0440","doi-asserted-by":"crossref","first-page":"e233640","DOI":"10.1001\/jamanetworkopen.2023.3640","article-title":"Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs","volume":"6","author":"Baker","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rmr.2025.10.001_bib0445","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/pds.3409","article-title":"Association between anti-TNF-\u03b1 therapy and interstitial lung disease","volume":"22","author":"Herrinton","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rmr.2025.10.001_bib0450","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ecco-jcc\/jjv135","article-title":"Six cases of lung injury following anti-tumour necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Lee","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rmr.2025.10.001_bib0455","doi-asserted-by":"crossref","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmr.2025.10.001_bib0460","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur Respir J [Internet]"},{"key":"10.1016\/j.rmr.2025.10.001_bib0465","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.rmr.2010.01.011","article-title":"Pneumopathie interstitielle diffuse et anti-TNF-alpha dans la polyarthrite rhumato\u00efde: deux formes diff\u00e9rentes?","volume":"27","author":"Schuller","year":"2010","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2025.10.001_bib0470","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/art.42860","article-title":"2023\u00a0American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0475","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.chest.2018.03.056","article-title":"Drug-induced sarcoidosis-like reactions","volume":"154","author":"Chopra","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2025.10.001_bib0480","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","article-title":"Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10\u00a0cases","volume":"48","author":"Daien","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.rmr.2025.10.001_bib0485","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.crad.2022.09.127","article-title":"Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy","volume":"78","author":"Li","year":"2023","journal-title":"Clin Radiol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0490","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12991","article-title":"Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database","volume":"288","author":"Cohen Aubart","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.rmr.2025.10.001_bib0495","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/MCP.0000000000000800","article-title":"Drug-induced sarcoidosis-like reactions","volume":"27","author":"Miedema","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.rmr.2025.10.001_bib0500","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/joim.13008","article-title":"The epidemic of drug-induced sarcoidosis-like reactions: a side effect that we can live with","volume":"288","author":"Judson","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.rmr.2025.10.001_bib0505","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12876-021-01948-6","article-title":"Development of pulmonary sarcoidosis in Crohn's disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review","volume":"21","author":"Kashima","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0510","doi-asserted-by":"crossref","first-page":"jjw155","DOI":"10.1093\/ecco-jcc\/jjw155","article-title":"Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy?","author":"Decock","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rmr.2025.10.001_bib0515","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1445-5994.2011.02612.x","article-title":"New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication","volume":"42","author":"Tong","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.rmr.2025.10.001_bib0520","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40744-022-00424-1","article-title":"Anti-TNF induced sarcoidosis-like disease in rheumatoid arthritis patients: review cases from the RA UCLouvain Brussels Cohort","volume":"9","author":"Theunssens","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.rmr.2025.10.001_bib0525","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10067-010-1603-3","article-title":"Sarcoid-like granulomatosis in patients treated with anti-TNF\u03b1 factors. A case report and review of the literature","volume":"30","author":"Kanellopoulou","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0530","first-page":"471","article-title":"Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases","volume":"26","author":"Toussirot","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rmr.2025.10.001_bib0535","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2169\/internalmedicine.2086-18","article-title":"Development of Propionibacterium acnes-associated sarcoidosis during etanercept therapy","volume":"58","author":"Isshiki","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.rmr.2025.10.001_bib0270","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2169\/internalmedicine.5281-20","article-title":"Propionibacterium acnes-associated sarcoidosis possibly initially triggered by interferon-alpha therapy","volume":"60","author":"Sawahata","year":"2021","journal-title":"Intern Med"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842525002426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842525002426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T11:45:16Z","timestamp":1764848716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842525002426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":54,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0761842525002426"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2025.10.001","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-TNF-a\u00a0: indications et toxicit\u00e9 en pneumologie","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS on behalf of SPLF.","name":"copyright","label":"Copyright"}]}}